Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.
暂无分享,去创建一个
J. Cayuela | H. Dombret | C. Preudhomme | S. de Botton | X. Thomas | S. Hayette | N. Vey | N. Boissel | A. Marceau | C. Berthon | T. Braun | Aline Renneville | O. Nibourel | C. Terré | M. Coudé | E. Raffoux | A. Pigneux | D. Caillot | J. Marolleau | M. Balsat | K. Celli-Lebras | C. Rodriguez | E. Lemasle | Emilie Lemasle
[1] Yashma Patel,et al. Assessment of Minimal Residual Disease in Standard-Risk AML. , 2016, The New England journal of medicine.
[2] J. Bourhis,et al. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. , 2015, Blood.
[3] D. Grimwade,et al. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"? , 2014, Blood.
[4] L. Bullinger,et al. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. , 2014, Blood.
[5] E. Hoster,et al. Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse , 2014, Haematologica.
[6] J. Cayuela,et al. MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin , 2014, Oncotarget.
[7] J. Cayuela,et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. , 2014, Blood.
[8] Francisco Cervantes,et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. , 2013, Blood.
[9] L. Bullinger,et al. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. , 2013, Blood.
[10] O. Landt,et al. The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. , 2013, Blood.
[11] J. Cayuela,et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. , 2013, Blood.
[12] R. Schlenk,et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach , 2012, Nature Reviews Clinical Oncology.
[13] H. Dombret,et al. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association , 2011, Leukemia.
[14] K. Döhner,et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Bob Löwenberg,et al. Review Articles (434 articles) , 2008 .
[16] P. Brown,et al. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity , 2009, Hematological oncology.
[17] A. Kohlmann,et al. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. , 2009, Blood.
[18] T. Haferlach,et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. , 2009, Blood.
[19] F. Lo‐Coco,et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Adam J Mead,et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. , 2008, Blood.
[21] M. Yao,et al. Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations , 2007, Leukemia.
[22] Brunangelo Falini,et al. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. , 2007, Blood.
[23] B. Falini,et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations , 2006, Leukemia.
[24] Bob Löwenberg,et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. , 2005, Blood.
[25] W. Hiddemann,et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. , 2005, Blood.
[26] Stefan Fröhling,et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. , 2005, Blood.
[27] J. Cayuela,et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. , 2005, Blood.
[28] Paola Fazi,et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.
[29] J. Cayuela,et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). , 2002, Blood.
[30] G. Ehninger,et al. Analysis of Flt3-activating Mutations in 979 Patients with Acute Myelogenous Leukemia: Association with Fab Subtypes and Identification of Subgroups with Poor Prognosis , 2022 .
[31] P. Grambsch,et al. Proportional hazards tests and diagnostics based on weighted residuals , 1994 .
[32] R Simon,et al. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. , 1984, Statistics in medicine.
[33] Nathan Mantel,et al. Evaluation of Response-Time Data Involving Transient States: An Illustration Using Heart-Transplant Data , 1974 .